HitGen Inc. (SHA: 688222), based in China, announced that its wholly owned subsidiary Vernalis (R&D) Ltd will collaborate with Hox Therapeutics Ltd, a private biotech firm dedicated to developing highly targeted cancer therapies, to create inhibitors aimed at undisclosed targets.
Vernalis will leverage its advanced protein science capabilities and Hit ID platform to produce target proteins, as well as to identify and characterize small molecule inhibitors against these targets. Hox will provide funding for the associated research efforts.- Flcube.com
